Pherecydes Pharma lists on Euronext Growth Paris

Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, opens the trading day in Paris.

Pherecydes Pharma is specialized in the research and development of anti-infective therapies based on bacteriophages. Phagotherapy is an innovative approach to treat bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells.